In this Ask the Expert segment, MPN expert Dr. Naval Daver of MD Anderson Cancer Center explains why the current pacritinib trial is on hold and shares the positive and negative learnings thus far. Dr. Daver applauds the FDA for the hold but still views pacritinib as a valuable addition to the MPN (myeloproliferative neoplasm) armamentarium.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo